|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP7A1 |
Gene summary for CYP7A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP7A1 | Gene ID | 1581 |
| Gene name | cytochrome P450 family 7 subfamily A member 1 | |
| Gene Alias | CP7A | |
| Cytomap | 8q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | P22680 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1581 | CYP7A1 | HCC1 | Human | Liver | HCC | 3.64e-12 | 6.88e-01 | 0.5336 |
| 1581 | CYP7A1 | HCC2 | Human | Liver | HCC | 1.25e-18 | 4.17e+00 | 0.5341 |
| 1581 | CYP7A1 | Pt13.a | Human | Liver | HCC | 1.41e-03 | 2.08e-01 | 0.021 |
| 1581 | CYP7A1 | Pt13.b | Human | Liver | HCC | 1.63e-04 | 1.24e-01 | 0.0251 |
| 1581 | CYP7A1 | Pt14.b | Human | Liver | HCC | 2.87e-02 | 1.39e-01 | 0.018 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
| GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
| GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
| GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
| GO:19026522 | Liver | HCC | secondary alcohol metabolic process | 100/7958 | 147/18723 | 3.26e-10 | 1.09e-08 | 100 |
| GO:00082032 | Liver | HCC | cholesterol metabolic process | 94/7958 | 137/18723 | 5.39e-10 | 1.72e-08 | 94 |
| GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
| GO:00161252 | Liver | HCC | sterol metabolic process | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
| GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
| GO:007233021 | Liver | HCC | monocarboxylic acid biosynthetic process | 129/7958 | 214/18723 | 1.08e-07 | 2.09e-06 | 129 |
| GO:00550882 | Liver | HCC | lipid homeostasis | 103/7958 | 167/18723 | 4.27e-07 | 7.18e-06 | 103 |
| GO:00066951 | Liver | HCC | cholesterol biosynthetic process | 43/7958 | 57/18723 | 4.37e-07 | 7.23e-06 | 43 |
| GO:19026531 | Liver | HCC | secondary alcohol biosynthetic process | 43/7958 | 57/18723 | 4.37e-07 | 7.23e-06 | 43 |
| GO:00161261 | Liver | HCC | sterol biosynthetic process | 47/7958 | 64/18723 | 5.00e-07 | 8.11e-06 | 47 |
| GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
| GO:00066942 | Liver | HCC | steroid biosynthetic process | 104/7958 | 173/18723 | 2.13e-06 | 2.91e-05 | 104 |
| GO:004218021 | Liver | HCC | cellular ketone metabolic process | 123/7958 | 211/18723 | 2.52e-06 | 3.37e-05 | 123 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| hsa033204 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
| hsa001202 | Liver | HCC | Primary bile acid biosynthesis | 14/4020 | 17/8465 | 3.49e-03 | 1.12e-02 | 6.22e-03 | 14 |
| hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
| hsa033205 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
| hsa001203 | Liver | HCC | Primary bile acid biosynthesis | 14/4020 | 17/8465 | 3.49e-03 | 1.12e-02 | 6.22e-03 | 14 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP7A1 | SNV | Missense_Mutation | c.133G>T | p.Ala45Ser | p.A45S | P22680 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CYP7A1 | SNV | Missense_Mutation | rs778199686 | c.818N>C | p.Leu273Pro | p.L273P | P22680 | protein_coding | tolerated(0.12) | benign(0.031) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CYP7A1 | SNV | Missense_Mutation | novel | c.1018N>A | p.Leu340Met | p.L340M | P22680 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CYP7A1 | SNV | Missense_Mutation | rs780668040 | c.692N>T | p.Ala231Val | p.A231V | P22680 | protein_coding | deleterious(0.01) | benign(0.146) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| CYP7A1 | SNV | Missense_Mutation | c.706N>A | p.Glu236Lys | p.E236K | P22680 | protein_coding | tolerated(0.2) | possibly_damaging(0.607) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYP7A1 | deletion | Frame_Shift_Del | novel | c.27delN | p.Ile10LeufsTer3 | p.I10Lfs*3 | P22680 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CYP7A1 | SNV | Missense_Mutation | novel | c.482C>T | p.Ser161Leu | p.S161L | P22680 | protein_coding | tolerated(0.37) | benign(0.003) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CYP7A1 | SNV | Missense_Mutation | c.206G>A | p.Cys69Tyr | p.C69Y | P22680 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CYP7A1 | SNV | Missense_Mutation | c.841G>A | p.Val281Met | p.V281M | P22680 | protein_coding | deleterious(0) | possibly_damaging(0.603) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CYP7A1 | SNV | Missense_Mutation | c.206G>A | p.Cys69Tyr | p.C69Y | P22680 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1581 | CYP7A1 | CYTOCHROME P450, DRUGGABLE GENOME, ENZYME | cholic acid | |||
| 1581 | CYP7A1 | CYTOCHROME P450, DRUGGABLE GENOME, ENZYME | atorvastatin | ATORVASTATIN | 16103896,15262185,26932749,21128988 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |